BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33661412)

  • 21. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma.
    Chan KH; Gu YL; Ng F; Ng PS; Seto WH; Sham JS; Chua D; Wei W; Chen YL; Luk W; Zong YS; Ng MH
    Int J Cancer; 2003 Jul; 105(5):706-9. PubMed ID: 12740922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of IgG directed against a recombinant form of Epstein-Barr virus BALF0/1 protein in patients with nasopharyngeal carcinoma.
    Shao Z; Borde C; Marchand CH; Lemaire SD; Busson P; Gozlan JM; Escargueil A; Maréchal V
    Protein Expr Purif; 2019 Oct; 162():44-50. PubMed ID: 31145974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients.
    Ayadi W; Karray-Hakim H; Feki L; Khabir A; Boudawara T; Ghorbel A; Daoud J; Frikha M; Hammami A
    J Med Virol; 2009 Aug; 81(8):1412-21. PubMed ID: 19551836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated antibody titers to Epstein-Barr virus prior to the diagnosis of Epstein-Barr-virus-associated gastric adenocarcinoma.
    Levine PH; Stemmermann G; Lennette ET; Hildesheim A; Shibata D; Nomura A
    Int J Cancer; 1995 Mar; 60(5):642-4. PubMed ID: 7860138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
    Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
    Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased antibody levels to stage-specific Epstein-Barr virus antigens in systemic autoimmune diseases reveal a common pathology.
    Sternbæk L; Draborg AH; Østerlund MT; Iversen LV; Troelsen L; Theander E; Nielsen CT; Jacobsen S; Houen G
    Scand J Clin Lab Invest; 2019; 79(1-2):7-16. PubMed ID: 30727744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Analysis of the Humoral Immune Response to the EBV Proteome across EBV-Related Malignancies.
    Argirion I; Pfeiffer RM; Proietti C; Coghill AE; Yu KJ; Middeldorp JM; Sarathkumara YD; Hsu WL; Chien YC; Lou PJ; Wang CP; Rothman N; Lan Q; Chen CJ; Mbulaiteye SM; Jarrett RF; Glimelius I; Smedby KE; Hjalgrim H; Hildesheim A; Doolan DL; Liu Z
    Cancer Epidemiol Biomarkers Prev; 2023 May; 32(5):687-696. PubMed ID: 36788424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Morishima S; Nakamura S; Yamamoto K; Miyauchi H; Kagami Y; Kinoshita T; Onoda H; Yatabe Y; Ito M; Miyamura K; Nagai H; Moritani S; Sugiura I; Tsushita K; Mihara H; Ohbayashi K; Iba S; Emi N; Okamoto M; Iwata S; Kimura H; Kuzushima K; Morishima Y
    Leuk Lymphoma; 2015 Apr; 56(4):1072-8. PubMed ID: 24975317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
    Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
    PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum.
    Cheng WM; Chan KH; Chen HL; Luo RX; Ng SP; Luk W; Zheng BJ; Ji MF; Liang JS; Sham JS; Wang DK; Zong YS; Ng MH
    Int J Cancer; 2002 Feb; 97(4):489-92. PubMed ID: 11802211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.
    Farrell RA; Antony D; Wall GR; Clark DA; Fisniku L; Swanton J; Khaleeli Z; Schmierer K; Miller DH; Giovannoni G
    Neurology; 2009 Jul; 73(1):32-8. PubMed ID: 19458321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma.
    Paramita DK; Fachiroh J; Artama WT; van Benthem E; Haryana SM; Middeldorp JM
    J Med Virol; 2007 Nov; 79(11):1710-21. PubMed ID: 17854043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma.
    Cai YL; Li J; Lu AY; Zheng YM; Zhong WM; Wang W; Gao JQ; Zeng H; Cheng JR; Tang MZ
    Asian Pac J Cancer Prev; 2014; 15(5):2001-6. PubMed ID: 24716925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody response to Epstein-Barr virus Rta protein in patients with nasopharyngeal carcinoma: a new serologic parameter for diagnosis.
    Feng P; Chan SH; Soo MY; Liu D; Guan M; Ren EC; Hu H
    Cancer; 2001 Oct; 92(7):1872-80. PubMed ID: 11745260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Combined detection of Epstein-Barr virus antibodies for serodiagnosis of nasopharyngeal carcinoma].
    Cai YL; Zheng YM; Wang W; Wei Y; Shen XX; Cheng JR; Wu YS; Gao JQ; Zhong WM; Li J
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec; 30(12):2746-8. PubMed ID: 21177196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-time Epstein-Barr virus PCR for the diagnosis of primary EBV infections and EBV reactivation.
    Luderer R; Kok M; Niesters HG; Schuurman R; de Weerdt O; Thijsen SF
    Mol Diagn; 2005; 9(4):195-200. PubMed ID: 16392898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
    Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
    Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seroreactivity against Epstein-Barr virus (EBV) among first-degree relatives of sporadic EBV-associated nasopharyngeal carcinoma in Indonesia.
    Hutajulu SH; Ng N; Jati BR; Fachiroh J; Herdini C; Hariwiyanto B; Haryana SM; Middeldorp JM
    J Med Virol; 2012 May; 84(5):768-76. PubMed ID: 22431025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of serum EBV-VCA IgG detection in assessing gastric cancer risk and prognosis in Northern Chinese population.
    Wang Z; Lv Z; Ding H; Xu Q; Sun L; Jing J; Yuan Y
    Cancer Med; 2018 Nov; 7(11):5760-5774. PubMed ID: 30306734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma Macrophage Inhibitory Cytokine-1 as a Complement of Epstein-Barr Virus Related Markers in Identifying Nasopharyngeal Carcinoma.
    Xing S; Li H; Pi Y; Zeng T; Huang Q; Ou G; Xue N
    Technol Cancer Res Treat; 2020; 19():1533033820956991. PubMed ID: 33025864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.